HighTower Advisors
TGTX icon

HighTower Advisors’s TG Therapeutics TGTX Stock Holding History

HighTower Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,500
Closed -$3K – 2507
2019
Q1 		$3K Buy
1,500
+500
+50% +$2.7K ﹤0.01% 2245
2018
Q4 		$1K Hold
1,000
– – ﹤0.01% 2197
2018
Q3 		$1K Buy
+1,000
New +$11.4K ﹤0.01% 2273

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

HighTower Advisors's TGTX Position: Q2 2026 in Review

HighTower Advisors reduced its TG Therapeutics (TGTX) stake by 20% in Q2 2026, selling an estimated $206K and leaving 20,250 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2171.

HighTower Advisors first reported a position in TGTX in Q1 2017 and has held it in 38 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • HighTower Advisors held 20,250 shares of TG Therapeutics worth $1.11M as of Q2 2026.
  • HighTower Advisors sold 5,023 TG Therapeutics shares in Q2 2026, an estimated $206K.
  • TG Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2171 holding.
  • HighTower Advisors first reported a position in TG Therapeutics in Q1 2017 and has held it in 38 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.